Dogwood Therapeutics Files Q1 2025 10-Q

Ticker: DWTX · Form: 10-Q · Filed: May 9, 2025 · CIK: 1818844

Dogwood Therapeutics, INC. 10-Q Filing Summary
FieldDetail
CompanyDogwood Therapeutics, INC. (DWTX)
Form Type10-Q
Filed DateMay 9, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, financials, pharmaceuticals

Related Tickers: DWTX

TL;DR

Dogwood Therapeutics (DWTX) filed its Q1 2025 10-Q. Financials are in.

AI Summary

Dogwood Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly Virios Therapeutics, Inc., reported financial data for its fiscal quarter. Key financial figures and stock information are detailed within the filing.

Why It Matters

This filing provides investors and analysts with the latest financial performance and position of Dogwood Therapeutics, Inc. for the first quarter of 2025.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Dogwood Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

Key Players & Entities

FAQ

What is the reporting period for this 10-Q filing?

The reporting period is for the quarter ended March 31, 2025.

What was Dogwood Therapeutics, Inc. formerly known as?

Dogwood Therapeutics, Inc. was formerly known as Virios Therapeutics, Inc. and Virios Therapeutics, LLC.

When was the company's name changed from Virios Therapeutics, Inc.?

The name change from Virios Therapeutics, Inc. occurred on December 17, 2020.

What is the company's primary business classification?

The company is classified under Pharmaceutical Preparations [2834].

What is the filing date of this 10-Q?

This 10-Q was filed on May 9, 2025.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 9, 2025 regarding Dogwood Therapeutics, Inc. (DWTX).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing